TXNIP May Mediate Insulin Sensitivity in Caloric Restriction

This article originally appeared here.
Share this content:
TXNIP May Mediate Insulin Sensitivity in Caloric Restriction
TXNIP May Mediate Insulin Sensitivity in Caloric Restriction

TUESDAY, Sept. 8, 2015 (HealthDay News) -- Caloric restriction (CR) improves peripheral insulin sensitivity, possibly by lowering insulin-stimulated thioredoxin-interacting protein (TXNIP) levels and enhancing non-oxidative glucose disposal, according to a study published online Aug. 31 in Diabetes.

Matthew L. Johnson, Ph.D., from Mayo Clinic College of Medicine in Rochester, Minn., and colleagues examined the underlying mechanism whereby CR improves insulin sensitivity in obese individuals. In 11 obese participants, the authors examined the effect of 16 weeks of CR on whole-body insulin sensitivity by pancreatic clamp before and after CR compared with a matched control period (nine participants).

The researchers found that CR increased the glucose infusion rate needed to maintain euglycemia during hyperinsulinemia, compared with control, indicating enhancement of peripheral insulin sensitivity. Improved insulin sensitivity was not associated with changes in skeletal muscle mitochondrial oxidative capacity or oxidant emissions, nor with changes in skeletal muscle ceramide, diacylglycerol, or amino acid metabolite levels. Lower insulin-stimulated TXNIP levels and enhanced non-oxidative glucose disposal were seen with CR.

"These results support a role for TXNIP in mediating the improvement in peripheral insulin sensitivity after CR," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Salmonella Outbreak in 26 States Linked to Raw Turkey Products

<i>Salmonella</i> Outbreak in 26 States Linked to Raw ...

40 individuals have been hospitalized to date; no deaths have been reported

FDA Recalls Drugs Containing Active Ingredient Valsartan

FDA Recalls Drugs Containing Active Ingredient Valsartan

All lots of non-expired products that contain valsartan supplied by Zhejiang Huahai being recalled

Atopic Dermatitis Places Heavy Burden on Patients

Atopic Dermatitis Places Heavy Burden on Patients

Overall and mental health, life satisfaction all impacted, especially for moderate, severe disease

is free, fast, and customized just for you!




Already a member?

Sign In Now »